Collaboration with BARDA and Prospects for Further Milestone Payments!
The collaboration with BARDA could trigger further milestone payments in the future!
The strategic perspective until 2030 looks promising. It will be important for the company to achieve study progress as planned!
Reading Time: 1 minute
Pharmaceutical companies and biotechs are currently back in favor with investors. In this context, it could be worthwhile to take a look at Basilea Pharmaceutica AG. The company specializes in drugs for serious bacterial infections and life-threatening fungal diseases. Currently, the collaboration with the US agency BARDA, which is part of the Department of Health and Human Services, is particularly exciting. On February 25th, Basilea announced the receipt of a milestone payment of six million USD for the further development of the novel oral...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
